z-logo
open-access-imgOpen Access
Managing Psychotropic Medications in Complex, Real-World Patients Using Comprehensive Therapeutic Drug Monitoring
Author(s) -
Jeffrey J. Sutherland,
Ryan D. Morrison,
J. Scott Daniels,
Stephen Milne,
Timothy P. Ryan
Publication year - 2017
Publication title -
acs chemical neuroscience
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.158
H-Index - 69
ISSN - 1948-7193
DOI - 10.1021/acschemneuro.7b00209
Subject(s) - polypharmacy , medicine , psychiatry , depression (economics) , psychotropic drug , therapeutic drug monitoring , anxiety , psychosis , drug , intensive care medicine , pharmacotherapy , economics , macroeconomics
There are multiple treatment options for depression, anxiety, psychosis, and other psychiatric disorders, and psychiatry patients are often comorbid with complex, polypharmacy treatment regimens. Unlike cardiovascular disease and diabetes, there are no readily available biomarkers to gauge treatment success with psychotropic medications, often resulting in subjective determination of medication therapy effectiveness. The physiochemical properties of psychiatric medications in general lend themselves to quantitative measurement in blood, offering an avenue to optimize treatment for each patient. Herein, we describe a novel application that employs comprehensive therapeutic drug monitoring of both psychiatric and nonpsychiatric medications to holistically personalize therapy for complex psychiatry patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom